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Abstract
Heparin (HP) and heparan sulfate (HS) play important roles in many biological events. Increasing
evidence has shown that the biological functions of HP and HS can be critically dependent upon
their precise structures, including the position of the iduronic acids and sulfation patterns.
However, unraveling the HP code has been extremely challenging due to the enormous structural
variations. To overcome this hurdle, we investigated the possibility of assembling a library of HP/
HS oligosaccharides using a preactivation-based, one-pot glycosylation method. A major
challenge in HP/HS oligosaccharide synthesis is stereoselectivity in the formation of the cis-1,4-
linkages between glucosamine and the uronic acid. Through screening, suitable protective groups
were identified on the matching glycosyl donor and acceptor, leading to stereospecific formation
of both the cis-1,4- and trans-1,4-linkages present in HP. The protective group chemistry designed
was also very flexible. From two advanced thioglycosyl disaccharide intermediates, all of the
required disaccharide modules for library preparation could be generated in a divergent manner,
which greatly simplified building-block preparation. Furthermore, the reactivity-independent
nature of the preactivation-based, one-pot approach enabled us to mix the building blocks. This
allowed rapid assembly of twelve HP/HS hexasaccharides with systematically varied and precisely
controlled backbone structures in a combinatorial fashion. The speed and the high yields achieved
in glycoassembly without the need to use a large excess of building blocks highlighted the
advantages of our approach, which can be of general use to facilitate the study of HP/HS biology.
As a proof of principle, this panel of hexasaccharides was used to probe the effect of backbone
sequence on binding with the fibroblast growth factor-2 (FGF-2). A trisaccharide sequence of 2-O-
sulfated iduronic acid flanked by N-sulfated glucosamines was identified to be the minimum
binding motif and N-sulfation was found to be critical. This provides useful information for
further development of more potent compounds towards FGF-2 binding, which can have potential
applications in wound healing and anticancer therapy.
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Heparin (HP) and heparan sulfate (HS), a member of the glycosaminoglycan (GAG) family,
are structurally related linear polyanionic polysaccharides.[1] The backbones of HP and HS
are composed of disaccharide subunits with D-glucosamine (GlcN) and uronic acid (either
L-iduronic (IdoA) or D-glucuronic acid (GlcA)) joined by alternating α-1,4 and β-1,4
linkages. The variation in uronic acid structures, the modification of the amino group in
GlcN (N-acetylation and sulfation) and differential sulfations of hydroxyl groups (2-O of the
uronic acid, 3-O and 6-O of the GlcN) lead to tremendous structural diversity in naturally
existing HP/HS.
Through interactions with a large number of polypeptides and proteins,[1–3] HP/HS play
crucial roles in numerous physiological processes such as viral infection, blood coagulation,
inflammatory response, cell adhesion, cell growth regulation, and tumor metastasis.[1,4–9]
The binding between HP/HS and their receptors can be critically dependent on the
saccharide structures, as exemplified by the high-affinity pentasaccharide sequence for
antithrombin III (ATIII) interaction,[10,11] with the removal of a single 3-O-sulfate in the
sequence reducing its activity by about 20000-fold. This knowledge led to the development
of Arixtra, a fully synthetic HP/HS pentasaccharide, which is approved for the treatment of
deep vein thrombosis.[10,12] However, despite this success, in many cases, it has been
difficult to unravel the biological activities encoded in the HP/HS structures, since it is
extremely challenging to obtain homogeneous HP/HS oligosaccharides from natural
sources. Furthermore, pharmaceutical HP is isolated from pig and bovine organs, which has
the potential risks of pathogen contamination and adulteration.[13,14] Synthesis, therefore,
provides a powerful means to access these complex molecules for the establishment of
detailed structure–activity relationships and analysis of HP/HS–protein interactions.[10,15–17]
Nature synthesizes HP and HS by modifying a homopolymer of heparosan GlcNAc-α-1,4-
GlcA through the actions of many enzymes, including N-deacetylase/N-sulfotransferase, C5-
epimerase, and O-sulfotransferases.[9,18] Most of these reactions are incomplete, thus
explaining the structural heterogeneity of native HP/HS. Attempts to harness the power of
enzymes for HP/HS synthesis have been reported.[19–24] However, the substrate specificities
of most of these enzymes are not yet well characterized, which hinders the application of
enzymatic approaches to the assembly of a diverse array of HP/HS oligosaccharides.
As an alternative to using enzymes, chemical syntheses of HP/HS oligosaccharides have
been actively pursued,[15–17] which can provide compounds with any sequences and
sulfation patterns as well as unnatural analogues. However, there are several challenges
associated with chemical synthesis: 1) with the rich functionalities in the HP/HS
oligosaccharides, selection of appropriate protective groups is crucial for backbone
extension and oligosaccharide functionalization. Even groups distant from the reactive sites
can have a profound effect on the outcome of glycosylation reactions.[25] 2) Stereochemical
control is crucial for HP/HS oligosaccharide synthesis, especially in the formation of the
cis-1,4-linkage between GlcN and uronic acid. Although, in general, the cis linkage is
preferred due to the anomeric effect, the stereoselectivity can vary drastically with the
building-block structures as well as reaction conditions[26–29] and the separation of anomers
can be tedious and at times impossible.[28] Thus, it is highly desirable that conditions can be
established for stereospecific formation of the cis-1,4-linkage.
The aforementioned challenges notwithstanding, the groups of van Boeckel, Petitou, and
Sinaÿ accomplished the first total synthesis of the ATIII binding HP pentasaccharide.[30–32]
This landmark achievement required about 60 synthetic steps, which served to highlight the
power of synthetic carbohydrate chemistry for saccharide-based drug development.[10] To
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minimize the number of steps required for protective group manipulation and aglycon
leaving group adjustment on intermediate oligosaccharides, strategies such as anomeric-
reactivity-based, one-pot synthesis[33] and selective activation[34] have been applied for the
synthesis of the ATIII-binding pentasaccharide. Several other targeted syntheses of HP/HS
pentasaccharides or longer have also been accomplished.[29,35–46] Despite these significant
progresses in the field, the target-oriented approaches required a new total synthesis for each
HP/HS structure. This is not efficient for structure–activity relationship (SAR) studies, in
which a number of HP/HS structures would be required to decipher the HP code.
For SAR studies, a diversity-oriented combinatorial approach needs to be developed to
access a wide range of HP/HS structures. This can be accomplished by using modular
building blocks, in which a set of properly protected building blocks can be converted to
multiple glycosyl donors and acceptors.[29,34,43,47,48] Recently, this strategy has been
applied to the preparation of HP/HS tetrasaccharides, which were subsequently used to
elucidate structural requirements for inhibition of β-secretase involved in Alzheimer’s
disease development.[35] To apply the modular strategy to higher oligosaccharides, the
availability of robust glycosylation chemistry is crucial, which must give high yields in
reactions of a variety of building blocks without the need for time-consuming individual
optimization.
Herein, we report the establishment of a modular assembly strategy for a panel of HP/HS
hexasaccharides using the preactivation-based, one-pot method.[49–53] This method granted
much more freedom in protective group selection, enabling us to achieve high-yielding
stereospecific glycosylations. Furthermore, the integration of several glycosylation reactions
into a single synthetic operation (one-pot) significantly expedited the glyco-assembly
processes, allowing the rapid construction of the hexasaccharide library in a combinatorial
fashion. The availability of these HP/HS hexasaccharides with well-defined sulfation
patterns and systematically varied backbone structures facilitated the SAR studies towards
binding with the fibroblast growth factor-2 (FGF-2), an important protein involved in
angiogenesis, cell proliferation, and embryonic development.[54,55]
Results and Discussion
Building-block design
There are two general routes to synthesize HP/HS oligosaccharides through uronic acids or
the corresponding hexose building blocks. Although uronic acid donors have been used
directly in GAG synthesis,[34,56,57] the presence of electron-withdrawing carboxylate
moieties may lower glycosylation yields.[58] Furthermore, the possibility of epimerization
limits the synthetic operations that can be performed on these compounds. Therefore, we
decided to explore glucoside and idoside as building blocks, which would be converted to
the corresponding uronic acids after oligosaccharide backbone formation.
Instead of using the popular trichloroacetimidate donors,[35,38,42] we chose thioglycosyl
building blocks because they give superior stability in storage and yet are readily activated
with thiophilic promoters.[59] We designed glucoside 1 and idoside 2, containing benzyl
(Bn), p-methoxybenzyl (PMB), and benzoyl (Bz) protecting groups, as suitable building
blocks. The 2-O-Bz group can direct the formation of 1,2-trans-glycosyl linkage through
neighboring group participation and be selectively removed to expose the hydroxyl group
for future sulfation. The PMB group on the 6-O position can be transformed for late-stage
oxidation-state adjustments. For the GlcN donors, we examined the azido moiety as a
nonparticipatory group (donors 3–6). Previously, Kerns and co-workers have discovered that
the use of an oxazolidinone moiety to simultaneously protect the C2-nitrogen and C3-OH of
a GlcN donor led to the exclusive formation of α-glycoside.[60] However, later studies
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showed that the oxazolidinone could cause side reactions due to its nucleophilicity, thus
limiting its wide usage in HP/HS oligosaccharide preparation.[26,61] Instead, the azido group
can not only facilitate the formation of α-linkages,[62] but also be selectively reduced to
amines in the presence of other protective groups for subsequent N-sulfation or N-
acetylation. However, the stereochemical outcome of using donors with the azido group is
dependent upon donor and acceptor structures as well as reaction conditions.[26–28] Thus
suitable protective group chemistry needs to be established for the construction of the
cis-1,4-linkages prior to oligosaccharide synthesis.
Evaluation of building blocks for disaccharide formation
The formation of a cis-1,4-linkage using GlcN donors was evaluated first (Table 1). The
donor 3 was preactivated[53,63] in the absence of any acceptors with the powerful promoter
pTolSOTf (1 equiv), which was formed in situ by reaction of pTolSCl with AgOTf at
−78°C. Upon the completion of donor activation, as determined by TLC analysis, the
glycosyl acceptor 2 was added together with a sterically hindered base, TTBP,[64] leading to
the formation of disaccharide product 7 in an excellent 84% yield with no β-linked trans-
disaccharide isolated (Table 1, entry 1). The newly formed α-1,4-linkage was confirmed by
NMR spectroscopy analysis (1J(C1′,H1′)=172.1 Hz).[65] Examination of GlcN donors with
different protective groups (4 and 5) demonstrated that this chemistry was robust because
they all gave complete cis selectivities (Table 1, entries 2 and 3).
It has been reported that acceptors with the gluco-configuration tend to produce
stereoisomeric mixtures in reactions with 2-azido GlcN donors.[29] Indeed, the reaction of
the tri-benzylated GlcN 3 with glucoside acceptor 1 led to the formation of both a and b
anomers of disaccharide 10 (α/β ≈2.5:1) (Table 1, entry 4). The differential stereochemical
outcome of using donor 3 to glycosylate gluco-configured acceptor 1 versus the idoside
acceptor 2 could be attributed to double stereodifferentiation.[66] Seeberger and co-workers
developed a clever approach that by locking the glucoside acceptor into the 1C4
conformation, thus converting the 4-OH into the idose-like axial position, high α selectivity
was obtained.[29] However, several additional synthetic steps were necessary to modify the
disaccharide products with suitable protective groups and aglycon leaving groups for further
chain elongation. Instead of changing the glycosyl acceptor, we explored the effect of donor
protective groups on stereoselectivities. Interestingly, GlcN donor 5 led to the exclusive
formation of the cis-linked disaccharide (1J-(C1′,H1′)=173.9 Hz) with no corresponding
trans-glycoside isolated (Table 1, entry 5). The levulinoyl acid (Lev)-protected donor 6 also
gave exclusively α anomer, but the glycosylation yield was lower (data not shown). With the
6-OAc moiety on donor 5, it is possible that the acetate might facilitate the formation of the
cis-glycosidic linkage through the remote neighboring group participation by the ester
carbonyl moiety.[67,68] To test this possibility, the 6-OAc was substituted with 6-OBn
(donor 4). The reaction of donor 4 with acceptor 1 maintained the exclusive cis selectivity
with good yield (Table 1, entry 6), thus demonstrating 6-OAc was not responsible for the
observed high stereoselectivity. Based on these observations, the tert-butyldimethyl silyl
(TBS) group is not only useful as a temporary protective group, masking the 4-OH of GlcN
for backbone elongation, but also plays an important role for facilitating the stereospecific
formation of the cis-1,4 glycosidic bond. Furthermore, the possibility of having either Bn or
Ac on the 6-O of GlcN without affecting stereoselectivities bestows great flexibility for
installing 6-O-sulfation in the future.
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Next, we examined the formation of the trans-1,4-linkage using the hexose donors. The
glycosylation of glucoside donor 13 with acceptor 14 led to the formation of disaccharide
product 15 in 53% yield with some acceptor (40%) recovered (Table 1, entry 7). In a similar
manner, idose donor 16 was preactivated and reacted with disaccharide 17, producing
trisaccharide 18 in 64% yield (Table 1, entry 8). Donor 16 was obtained as a side product
during preparation of idoside 2, thus making full use of all available building blocks.
Stepwise and one-pot synthesis of HP/HS hexasaccharides
With the successful establishment of stereospecificity in disaccharide formation, we moved
on to oligosaccharide assembly. In the absence of neighboring group participation, the size
of the glycosylating agent and the nature of the nucleophile can have unpredictable effects
on the stereo-selectivity.[28,50,69] For example, although a 2-azido GlcN donor reacted with
an IdoA monosaccharide acceptor to form a cis-1,4-linked HP trisaccharide exclusively,
reaction between a tetrasaccharide donor and disaccharide acceptor with similar protective
groups led to an inseparable anomeric mixture of hexasaccharides.[28] Therefore, to avoid
this potential complication in stereochemistry, for oligosaccharide chain extensions, we
chose disaccharide donors (e.g., 9 and 11) with the idose or glucose at the reducing end and
participating acyl groups at the 2-O-positions. The TBS group in 11 was removed to
generate acceptor disaccharide 19 (Scheme 1a). Interestingly, although donor 13
successfully reacted with acceptor 14, the glycosylation of disaccharide 11 by 19 failed to
yield the desired tetrasaccharide. Instead, the major side product isolated was the anhydro
compound 20 (40–50% yield) (Scheme 1b). This side product is presumably formed through
the participation of electron-rich 6-OPMB to stabilize the oxa-carbenium ion followed by
cleavage of the PMB moiety.[52] The differential outcome in glycosylations with
monosaccharide versus disaccharide building blocks despite similar protective groups used
is probably due to the lower reactivities of the disaccharides resulting from the presence of
additional glycosyl units.[70] The reduction in glycosylation rate could favor the competing
side reaction from remote participation of the OPMB group.
To overcome this difficulty, the 6-OPMB group in disaccharide 11 was replaced with OLev
(donor 21), from which two disaccharide acceptors 22 and 23 were generated in high yields
(Scheme 2a, b). Gratifyingly, glycosylation of 22 by 21 proceeded smoothly to afford the
desired tetrasaccharide 24 in 64% isolated yield with exclusive β selectivity (Scheme 2c).
Subsequent reaction of 24 with disaccharide 23 produced hexasaccharide 25 in 81% yield.
The stereochemistry of 25 was confirmed by NMR spectroscopy[65] and MS analysis with
three α-glycosyl linkages (1J(C1,H1) = 174.9, 173.9, 173.9 Hz) and three β-linkages
(1J(C1,H1) = 161.9, 161.9, 159.6 Hz).
Encouraged by the results of stepwise glycosylations, we performed the one-pot assembly of
25 (Scheme 3a).[59] Pre-activation of the disaccharide donor 21 (1 equiv) at −78°C with
pTolSCl/AgOTf was followed by the addition of the first disaccharide acceptor 22 (0.9
equiv). The reaction temperature was raised to −10°C to expedite glycosylation and the
acceptor was 22 completely consumed in 2 h based on TLC analysis. The reaction
temperature was cooled back to −78°C, followed by addition of the second disaccharide
acceptor 23 (0.8 equiv) and pTolSCl/AgOTf. The fully protected hexasaccharide 25 was
obtained in 71% yield in one pot in 5 h and its structure was identical with that from the
stepwise reactions. The higher yield from the one-pot reaction compared with the stepwise
synthesis was presumably due to less product loss during workup and purification. The one-
pot reaction condition were general, which were extended without any optimization to the
one-pot assembly of hexasaccharide 26 by sequential glycosylations of three idose-
containing disaccharides 27, 17, and 28 in 50% yield (Scheme 3b). The presence of six α-
linkages (1J(C1,H1) =172.1 (03), 171.6, 171.1 Hz (02)) unequivocally confirmed the
stereochemistry of compound 26. The TBS moieties at the nonreducing end of 25 and 26
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can be selectively removed to generate hexasaccharide acceptors for future synthesis of
longer oligosaccharides.
The speed and high overall yield using only close to stoichiometric amounts of building
blocks in the assembly of hexasaccharides 25 and 26 highlighted the advantages of our
approach. In addition, the building blocks used have the same protective group patterns, thus
possessing similar anomeric reactivities.[70,71] For the popular reactivity-based armed–
disarmed strategy, time-consuming protective group manipulations of these building blocks
would be required to render the glycosyl donor much more reactive than the acceptor for
selective donor activation.[70–72] As the preactivation-based protocol can be performed
independent of the anomeric reactivities, it allowed us to use the building blocks directly
without the need to fine-tune their anomeric reactivities, thus simplifying building-block
preparation. This will be particularly advantageous in oligosaccharide library preparation, in
which a large number of structures need to be prepared.
One-pot modular synthesis of an HP-like hexasaccharide library for studying HP/HS FGF-2
interactions
The fibroblast growth factors (FGFs) are involved in many important developmental and
physiological processes.[54,55] FGFs bind with endogenous HP/HS, which is essential for
high-affinity interactions with the membrane-bound FGF receptors subsequently resulting in
signal transduction for cell proliferation and growth.[73–76] Therefore, the identification of
strong-binding HP/HS oligosaccharides can lead to the development of agents mediating the
biological functions of FGFs, which can have important therapeutic applications in areas
including wound healing, angiogenesis, and cancer therapy.[77,78]
The basic fibroblast growth factor (FGF-2) is a member of the FGF family. SAR studies on
FGF-2 binding with HP/HS have shown that the 3-O- and 6-O-sulfates on the GlcN of HP/
HS are not essential, whereas 2-O-sulfation of the uronic acid is important.[24,38,79,80] The
conversion of N-sulfation to acetamide significantly reduced the activity.[38] However, the
activity lost by N-acylation could be partially regained by O-sulfation.[80] Whereas much
study has been devoted to examine the effects of sulfation on FGF-2 binding, the
information regarding backbone sequence preference is not very well established.[38,46] The
majority of studies performed to date have used HP/HS oligosaccharides mainly containing
of IdoA.[38,46,81,82] Nevertheless, GlcA-containing oligosaccharides have been shown to
bind and activate FGF-2.[83] Therefore, a systematic investigation on the effects of backbone
structures can further advance our understanding of the FGF-2 activities.
Since HP/HS hexasaccharides have been shown to be biologically active,[78] we decided to
focus on the preparation of a library of hexasaccharides. As 3-O- and 6-O-sulfation of GlcN
are not essential for FGF-2 binding,[6,38,84] this library of 12 hexasaccharides contains
systematically varied backbone sequences and 2-O-sulfated uronic acids (i.e., IdoA2S and
GlcA2S) to probe the effects of the number and location of IdoA as well as N-sulfation.
To acquire this library efficiently, we developed a divergent approach to access all of the
necessary modules from two common thioglycosyl disaccharides 27 and 31. Specifically,
the 4-OTBS group in disaccharide 27 was selectively removed by treatment with HF in
pyridine to give the disaccharide acceptor 17 in 92% yield as the disaccharide module for
backbone elongation. The newly liberated hydroxyl group in 17 was benzylated as promoted
by silver oxide leading to the capping disaccharide 29 in 94% yield. It should be emphasized
that the mild basic condition employed for benzylation did not affect the base-sensitive Lev
and Bz groups in the molecule. Glycosylation of disaccharide 27 with N-
(benzyl)benzyloxycarbonyl 3-amino propanol followed by TBS removal gave the reducing
end module 30 in 89% yield with an exclusive trans selectivity due to neighboring group
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participation by the 2-OBz moiety (Scheme 4a). In a similar manner, three glucose-
containing disaccharides 32, 33, and 34 were prepared divergently from disaccharide 31
(Scheme 4b).
With the disaccharide building blocks in hand, we explored the construction of the
hexasaccharide library. Previously, Bonnaffé and co-workers developed an interesting
approach, in which three HP/HS tetrasaccharides have been obtained by subjecting three
glycosyl acceptors to simultaneous glycosylation in a mixture synthesis.[85] However, the
subsequent demixing required time-consuming HPLC separation of the three differentially
sulfated glycoside products. Instead of relying on mixture synthesis, we adopted a parallel
reaction approach, in which a single desired product was to be obtained from each reaction.
Since the preactivation method was independent of the anomeric reactivities, it allowed us to
mix the available building blocks rapidly to create sequence diversity. For example,
sequential glycosylations using three disaccharide modules 29, 17, and 34 following the
one-pot procedure gave hexasaccharide 35 with the idose, idose, and glucose backbone
structure in 54% yield within just a few hours (Table 2, entry 1). Simple substitution of 17
by 32 in the one-pot synthesis generated hexasaccharide 36 with the idose, glucose, and
glucose backbone structure (Table 2, entry 2). In a similar manner, hexasaccharides 37–40
were produced in good yields with potential N- and 2-O-sulfation sites and precisely
positioned idose moieties (Table 2, entries 3 to 6). Combined with hexasaccharides 25 and
26, these compounds covered all of the possible hexasaccharide backbone sequences with
GlcN at the nonreducing end. Although the glycosylation outcome can often be highly
dependent on building-block structures, it is remarkable that all of the one-pot reactions
tested here proceeded well without individual reaction optimization. This highlighted the
robustness of our protective group chemistry and glycosylation technology, which should be
applicable for future preparation of larger HP/HS oligosaccharide library.
Deprotection of the hexasaccharide 35 was performed by first selectively removing the three
Lev protective groups with hydrazine, followed by oxidation employing 2,2,6,6-tetra-
methyl-1-piperidinyloxy (TEMPO)/NaOCl and acid protection to facilitate product
characterization (Scheme 5).[42,52,86] Saponification of the hexasaccharide by LiOH, H2O2,
and KOH, followed by Staudinger reduction of the azido group provided compound 41 in
75% yield for the four steps. Sulfation of the free hydroxyls and amines in 41 with
subsequent catalytic hydrogenation over the Pearl-man catalyst produced HP-like
hexasaccharide 42. The aminopropyl group at the reducing end should not interfere with
FGF-2 binding;[38] it can be useful for future development of multivalent constructs[87] as
well as microarrays.[38] Alternatively, the structurally related hexasaccharide 43 was
obtained by selective amine acetylation of 41 followed by O-sulfation and catalytic
hydrogenation.[33,42] Hexasaccharides 44 to 53 were prepared analogously, which contain
systematically varied backbones, the 2-O-sulfates on the uronic acid units and the amino
groups are either sulfated or acetylated.
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The binding between the synthetic HP/HS hexasaccharides and FGF-2 was examined
through a competition assay[24] with radiolabeled HS polysaccharides.[24] 35S-labeled HS
was harvested from Chinese hamster ovary cells that were grown in the medium containing
sodium [35S]sulfate. The complex formed between [35S]HS and FGF-2 could be captured on
a nitrocellulose membrane. For the binding assay, the synthetic hexasaccharides or
unlabeled HS were incubated with [35S]HS and FGF-2. The FGF-2 binding compounds
would compete with [35S]HS, resulting in its dissociation from FGF-2 and consequently
lower radioactivity on the membrane.
The panel of hexasaccharides was assayed and found to exhibit differential potencies in
FGF-2 binding (Figure 1). Although compound 51 contained the same number and location
of sulfates, it was a much weaker binder than other 2-O- and N-sulfated hexasaccharides
(compounds 42, 44, 46, 47, 49, and 53). This suggests that FGF-2 binding is not a sole
reflection of charge density; rather the specific HS sequence is important. From the SAR
analysis, it is clear that the trisaccharide domain N-sulfated GlcN (GlcNS)-IdoA2S-GlcNS
represents a minimum FGF-2 binding motif, which can form a kink in polysaccharide chains
as induced by FGF binding.[88] The absence of the GlcNS unit at the reducing end of
IdoA2S as in hexasaccharide 51 significantly reduced the FGF-2 affinity. The IdoA2S
structure is also important because the corresponding GlcNS-GlcA2S-GlcNS was not
effective in binding. This is presumably due to the conformational plurality of the IdoA
ring.[89] Furthermore, the replacement of GlcNS with N-acetylated GlcN (hexasaccharides
43, 45, 48, 50, and 52) led to the complete loss of FGF-2 binding, which was consistent with
previous reports albeit on different backbone structures.[38] 2-O-Sulfation of the uronic acids
could not compensate for the loss of N-sulfates in these hexasaccharides. With the large
groovelike binding site on FGF-2 to accommodate the polysaccharide,[74] the potency of the
oligosaccharides can be further enhanced by elongating their length.
Conclusion
We have successfully developed a methodology to assemble a library of HP/HS
oligosaccharides. Matched donor and acceptor pairs were identified to allow stereospecific
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formation of the disaccharide building blocks, including those containing the challenging
cis-1,4-linkages. Preactivation-based, one-pot sequential glycosylations using the
disaccharides led to the rapid construction of hexasaccharides in high yields. To test the
generality of the methodology, the synthesis of an HP/HS hexasaccharide library was then
explored. As our reaction protocol does not require the glycosyl donor to have higher
anomeric reactivities than the acceptor, building blocks with similar protective groups,
hence similar anomeric reactivities, can be employed without the need for time-consuming
protective group adjustment to achieve exact anomeric reactivities. Thus, mixing six
disaccharide modules divergently derived from two common intermediate disaccharides
allowed combinatorial synthesis of 12 hexasaccharides with systematically varied backbone,
precisely positioned IdoA units, and well-defined amine functionalization. The availability
of such a library allowed the establishment of important structural features for HS
interactions with the growth factor FGF-2. It was found that N-sulfation and trisaccharide
motif GlcNS-IdoA2S-GlcNS is important for FGF-2 binding and GlcA2S cannot substitute
IdoA2S effectively. This knowledge can provide valuable leads for further development of
novel HP/HS-based therapeutics targeting FGF-2.
The successful synthesis of the hexasaccharide library and the high synthetic efficiency
achieved herein showcased the power of our synthetic methodology. With further
development, this can provide a promising option for the rapid assembly of HP/HS
oligosaccharides. With their well-defined structures, the synthetic oligosaccharides can
greatly aid in the analysis of many HP–protein interactions and deciphering the structural
information encoded in HP sequences.
Experimental Section
General procedure for preactivation-based single-step glycosylation
A solution of donor (60 μmol) and freshly activated 4 Å molecular sieves (200 mg) in
CH2Cl2 (2 mL) was stirred at room temperature for 30 min, and cooled to −78°C, which
was followed by the addition of AgOTf (47 mg, 180 μmol) dissolved in Et2O (1 mL)
without touching the wall of the flask. After 5 min, orange-colored pTolSCl (9.5 μL, 60
μmol) was added to the solution through a microsyringe. Since the reaction temperature was
lower than the freezing point of pTolSCl, pTolSCl was added directly into the reaction
mixture to prevent it from freezing on the flask wall. The characteristic yellow color of
pTolSCl in the reaction solution dissipated within a few seconds, indicating depletion of
pTolSCl. After the donor was completely consumed, according to TLC analysis (about 5
min at −78°C), a solution of acceptor (54 μmol) in CH2Cl2 (0.2 mL) was slowly added
dropwise by using a syringe (one equivalent of TTBP was added with acceptor if the donor
or acceptor contained the PMB protecting group). The reaction mixture was warmed to
−20°C under stirring over 2 h. Then, the mixture was diluted with CH2Cl2 (20 mL) and
filtered over Celite. The Celite was further washed with CH2Cl2 until no organic compounds
were observed in the filtrate by TLC analysis. All solutions in CH2Cl2 were combined and
washed twice with a saturated aqueous solution of NaHCO3 (20 mL) and twice with water
(10 mL). The organic layer was collected and dried over Na2SO4. After removal of the
solvent, the desired oligosaccharide was purified from the reaction mixture by silica gel
flash chromatography.
General procedure for preactivation-based three-component one-pot glycosylation
A solution of donor (60 μmol) and freshly activated 4 Å molecular sieves (200 mg) in
CH2Cl2 (2 mL) was stirred at room temperature for 30 min, and cooled to −78°C, which
was followed by addition of AgOTf (47 mg, 180 μmol) dissolved in Et2O (1 mL) without
touching the wall of the flask. After 5 min, orange-colored pTolSCl (9.5 μL, 60 μmol) was
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added to the solution through a microsyringe. Since the reaction temperature was lower than
the freezing point of pTolSCl, pTolSCl was added directly into the reaction mixture to
prevent it from freezing on the flask wall. The characteristic yellow color of pTolSCl in the
reaction solution dissipated within a few seconds, indicating depletion of pTolSCl. After the
donor was completely consumed, according to TLC analysis (about 5 min at −78°C), a
solution of acceptor (54 μmol) in CH2Cl2 (0.2 mL) was slowly added dropwise by using a
syringe. The reaction mixture was warmed to −20°C under stirring in 2 h and then the
mixture was cooled to −78°C, followed by sequential additions of AgOTf (16 mg, 60 μmol)
in Et2O (1 mL), the second acceptor (48 μmol) in CH2Cl2 (1 mL). The mixture was stirred
for 5 min at −78°C and then pTolSCl (7.6 μL, 48 μmol) was added to the solution. The
reaction mixture was warmed to −20°C under stirring in 2 h. Then the mixture was diluted
with CH2Cl2 (20 mL) and filtered over Celite. The Celite was further washed with CH2Cl2
until no organic compounds were observed in the filtrate by TLC analysis. All solutions in
CH2Cl2 were combined and washed twice with a saturated aqueous solution of NaHCO3 (20
mL) and twice with water (10 mL). The organic layer was collected and dried over Na2SO4.
After removal of the solvent, the desired oligosaccharide was purified from the reaction
mixture by silica gel flash chromatography.
General procedure for deprotection of PMB
The PMB-protected compound (1.0 equiv) was dissolved in a mixture of CH2Cl2/H2O (for
0.5 g of compound, 9 mL/1 mL) and the solution was cooled to 0°C. DDQ (1.1 equiv) was
added to the solution and the mixture was stirred at room temperature for 3 h. The mixture
was filtered, diluted with CH2Cl2 (50 mL), and the organic phase was washed with H2O
until the solution became colorless. The solvent was concentrated in vacuo and the
compound was purified by silica gel column chromatography.
General procedure for protection of 6-OH with Lev
The compound containing 6-OH (1 equiv) was dissolved in CH2Cl2 (for 0.5 g of compound,
5 mL), followed by addition of Lev (1.4 equiv), EDC·HCl (1.6 equiv) and DMAP (0.1
equiv). The mixture was stirred at room temperature over-night and then was diluted with
CH2Cl2 (100 mL). The organic phase was washed with saturated NaHCO3 and then dried
over Na2SO4. The solvent was concentrated in vacuo and the compound was purified by
silica gel column chromatography.
General procedure for deprotection of TBS
The TBS-protected compound was dissolved in pyridine (for 100 mg of compound, 1.5 mL).
The mixture was cooled to 4°C, followed by addition of HF in pyridine (0.75 mL, 65–70%
in pyridine). The mixture was stirred at room temperature overnight and then the residue
was diluted in EtOAc (100 mL), washed with saturated NaHCO3, and then the organic layer
was dried over Na2SO4. The solvent was concentrated in vacuo and the compound was
purified by silica gel column chromatography.
General procedure for deprotection of Lev
The Lev-protected compound (1 equiv) was dissolved in pyridine (for 150 mg of compound,
2.4 mL) and acetic acid (1.6 mL). The mixture was cooled to 0°C, followed by addition of
hydrazine monohydrate (5 equiv for each Lev). The mixture was stirred at 0°C for 2 h and
then was quenched with acetone (0.28 mL). The mixture was stirred at room temperature for
1 h and the acetone was evaporated under vacuum. The residue was diluted with EtOAc (50
mL) and washed with saturated NaHCO3, 10% HCl, and water, and the organic phase was
dried over Na2SO4. The solvent was concentrated in vacuo and the compound was purified
by silica gel column chromatography.
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General procedure for 6-OH oxidation to carboxylic acid and benzyl ester formation
H2O (2 mL), 1 M KBr (1.5 equiv per OH), 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)
(1 equiv for each OH), 0.5 M NaHCO3 (10 equiv per OH) and Bu4NBr (10 equiv per OH)
were consecutively added to a solution of 6-OH-containing compound (for 100 mg of
compound, 1 equiv) in CH2Cl2 (2 mL) at room temperature. The mixture was cooled to 0°C,
followed by slow addition of NaOCl (100 equiv per OH). The pH value of the mixture was
calibrated with 0.5 M NaOH to maintain at pH 10 and the resulting solution was warmed
slowly to room temperature (maintain at pH 10). After stirring for 3 h, the CH2Cl2 was
evaporated under vacuum and the residue was diluted with EtOAc (50 mL) and washed with
10% HCl, saturated NaHCO3, and water. The organic phase was dried over Na2SO4,
filtered, and the solvents were removed in vacco. Without separation, the resulting residue
was dissolved in CH2Cl2 (5 mL), followed by addition of phenyldiazomethane in diethyl
ether until the color turned red. The mixture was stirred at room temperature for 1 h and then
was diluted with CH2Cl2 (50 mL), and the organic phase was washed with saturated
NaHCO3 and dried over Na2SO4. The solvent was concentrated in vacuo and the compound
was purified by silica gel column chromatography.
General procedure for saponification
The mixture of compound (for 100 mg of compound, 1 equiv), THF (2.5 mL), and 1 M
LiOH (13 equiv per COOBn) was cooled to −5°C, followed by addition of H2O2 (150 equiv
per COOBn, 30%). The mixture was stirred at room temperature for 16 h and then MeOH (6
mL) and 3 M KOH (80 equiv per COOBn) were added to the solution. The mixture was
stirred for another 24 h and then was acidified with 10% HCl, concentrated to dryness. The
resulting residue was purified by quickly passing through a short silica gel column (4:1,
CH2Cl2-MeOH).
General procedure for azide reduction
1 M PMe3 solution in THF (5 equiv per N3), 0.1 M aqueous solution of NaOH (2.6 equiv
per N3), and H2O (2 mL) were added consecutively to a solution of azide-containing
compound (for 50 mg of compound, 1 equiv) in THF (7 mL). The mixture was stirred at
room temperature overnight and neutralized with 0.1 M HCl until pH 7. The mixture was
concentrated to dryness and the resulting residue was purified by quickly passing through a
short silica gel column (4:1, CH2Cl2/MeOH).
General procedure for O-sulfation
The mixture of OH-containing compound (for 20 mg of compound, 1 equiv), DMF (1 mL),
and SO3·NEt3 (5 equiv per OH) was stirred at 55°C for 24 h. The mixture was quenched by
adding Et3N (0.2 mL) and then diluted with CH2Cl2/MeOH (1 mL/1 mL). The resulting
solution was layered on the top of a Sephadex LH-20 chromatography column that was
eluted with CH2Cl2/MeOH (1/1, v/v). The solvent was evaporated to dryness under vacuo
without further purification.
General procedure for N-sulfation
A mixture of NH2-containing compound (for 20 mg of compound, 1 equiv), pyridine (1
mL), Et3N (0.2 mL), and SO3·Pyridine (5 equiv per NH2) was stirred at room temperature
for 3 h. The mixture was diluted with CH2Cl2/MeOH (1 mL/1 mL) and the resulting
solution was layered on the top of a Sephadex LH-20 chromatography column that was
eluted with CH2Cl2/MeOH (1/1, v/v). The solvent was evaporated to dryness under vacuo
without further purification.
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General procedure for selective N-acetylation
A mixture of OH, NH2-containing compound (for 12 mg of compound, 1 equiv), Ac2O (5
equiv per NH2), Et3N (15 μL), and MeOH (1 mL) was stirred at room temperature for 5 h.
The mixture was diluted with CH2Cl2/MeOH (1 mL/1 mL) and the resulting solution was
layered on the top of a Sephadex LH-20 chromatography column that was eluted with
CH2Cl2/MeOH (1/1, v/v). The solvent was evaporated to dryness under vacuo without
further purification.
General procedure for global debenzylation
A mixture of the Bn-containing compound (for 12 mg of compound, 1 equiv), MeOH/H2O
(4 mL/2 mL), and Pd(OH)2 (100 mg) was stirred under H2 at room temperature overnight
and then filtered. The filtrate was concentrated to dryness under vacuum and then diluted
with H2O (15 mL). The aqueous phase was further washed with CH2Cl2 (3×5 mL) and
EtOAc (3×5 mL) and then the aqueous phase was dried under vacuum. The crude product
was further purified by size exclusion chromatography (G-15) and then eluted from a
column of Dowex 50WX4-Na+ to convert the compound into the sodium salt form.
Determination of the binding of [35S]HS and FGF-2
The binding of [35S]HS and FGF-2 was carried out using a “filter-trapping” assay.[24]
Briefly, FGF-2 (1 μg) was incubated with HS polysaccharide (1.6 μg) or various amounts of
hexasaccharides in PBS buffer (200 μL) at room temperature for 30 min. Then, [35S]HS
(4500 cpm) was added into the reaction mixture followed by incubation at 37°C for 90 min.
The mixture was then spotted onto nitrocellulose membrane. The membrane was thoroughly
washed with PBS and a PBS-based buffer containing 280 mM NaCl. The spotted membrane
was mixed with scintillation fluid to measure 35S-counts to determine the percentage of
residual [35S]HS bound to FGF-2.
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Refer to Web version on PubMed Central for supplementary material.
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FGF2 (1 μg) was incubated with 10 (empty bar) or 40 μg (filled bar) unlabeled
hexasaccharides 42–53 or HS (1.6 μg) in PBS buffer (200 μL) at room temperature for 30
min. Then, [35S]HS (4500 cpm) was added to the mixture followed by incubation at 37°C
for 90 min. The data represent the average of four or more experiments with the error bars
showing standard deviations. The control was the sample without any hexasaccharides or
unlabeled HS. The percentage of residual [35S]HS binding was calculated by dividing the
residual 35S counts on the membrane with sample incubation by control counts. For more
details, see the Experimental Section.
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Synthesis of disaccharide acceptor 19 and evaluation of tetrasaccharide formation.
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Synthesis of disaccharide building blocks 21–23 and hexasaccharide 25. Reagents and
conditions: a) 2,3-dichloro-5,6-dicyano p-benzoquinone (DDQ), CH2Cl2/H2O, RT, 3 h;
LevOH, N′-(3-diemthylaminopropyl)-N-ethylcarbodiimide (EDC), 4-dimethylaminopyridine
(DMAP), CH2Cl2, RT, 2 h; b) HF in pyridine, pyridine, RT, overnight; c) pTolSCl/AgOTf,
CH2Cl2/Et2O, EtOH, −78 to −10 °C; d) pTolSCl/AgOTf, CH2Cl2/Et2O, then 22, −78 to
−10 °C; e) pTolSCl/AgOTf, 23, CH2Cl2/Et2O, −78 to −10°C.
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One-pot synthesis of HP-like hexasaccharides 25 and 26.
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Divergent functionalization of disaccharide building blocks from common intermediates.
Reagents and conditions: a) HF in pyridine, pyridine, RT, overnight; b) BnBr, Ag2O,
molecular sieves, RT, 5 h; c) pTolSCl/AgOTf, CH2Cl2/Et2O, N-(benzyl)benzyloxycarbonyl
3-amino propanol, −78 to −10 °C.
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Deprotection and selective N-derivatization led to two HP/HS hexasaccharides (42, 43)
divergently from 35. Reagents and conditions: a) NH2NH2, acetic acid, pyridine, 0 °C,
TEMPO, NaOCl, KBr, Bu4NBr, NaHCO3, CH2Cl2/H2O, 0 °C to RT, NaClO2, then
PhCHN2; b) LiOH, H2O2, THF, RT, then NaOH, Me3P, NaOH, THF, H2O; c) SO3·Et3N,
DMF, 55°C, SO3·Py, Et3N/pyridine, H2, Pd(OH)2; d) Ac2O, MeOH, Et3N, RT; SO3·Et3N,
DMF, 55 °C, H2, Pd(OH)2.
Wang et al. Page 21

























Wang et al. Page 22
Table 1
Evaluation of glycosyl donors.[a]
Entry Donor Acceptor Disaccharide Yield [%]
1 3 2 7 84 (α only)
2 5 2 8 84 (α only)
3 4 2 9 79 (α only)
4 3 1 10 73 (α/β=2.5:1)
5 5 1 11 89 (α only)
6 4 1 12 75 (α only)
7 13 14 15 53
8 16 17 18 64
[a]
TTBP=2,4,6-tri-tertbutyl pyrimidine, pTolSCl=p-toluenesulfenyl chloride.
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